New treatment for moderate to severe atopic dermatitis shows promising long-term results

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab -- a novel, patient-tailored monoclonal antibody therapy -- showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped.

from Latest Science News -- ScienceDaily https://ift.tt/iZuaw5v